In this issue of Clinical Medicine & Research, Musana et al. 3 describe successful endoscopic treatment of pancreatic pseudocysts tracking within the mediastinum, producing a pancreaticopleural fistula and cardiac compression. Since the pseudocysts were caused by the mechanism of pancreatic ductal obstruction with leak, successful resolution was achieved by extraction of the obstructing pancreatic duct stone.
Traditional management of pancreatic fluid collections, such as the one presented by Musana et al. 3 has been medical 4 and/or surgical, 5, 6 and occasionally radiological (percutaneous). [7] [8] [9] Although endoscopic therapy for this complication has been previously described, [10] [11] [12] surgery remains the gold standard for interventional therapy of pancreatic disease by which other therapies are judged. This is because endoscopic therapy (endoscopic retrograde cholangiopancreatography) is the "new kid" on the block for the treatment of pancreatic disease, second to surgery, the only available non-medical therapy that has proven itself. 13 Well, the new kid has been around now for over 20 years. The first successful endoscopic drainage therapy for 83
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Todd H. Baron pancreatic pseudocysts using transgastric and transduodenal stent placement was described by Kozarek 14 in 1985. Since that time endoscopic therapy for pancreatic disease has included drainage of acute and chronic pseudocysts and pancreatic necrosis, 15 treatment of pancreatico-cutaneous fistulae following surgical and percutaneous drainage, and treatment of ductal disruptions from trauma. 13 On the front of pain therapy, by relieving obstruction of the main pancreatic duct in the setting of chronic pancreatitis, endoscopic therapy has fared well in selected patients. 13 Truly, pancreatic endotherapy has come a long way, but has it been completely embraced as frontline therapy for pancreatic disease in which an intervention is necessary? I believe it has not, partly because of the lack of education of physicians across many disciplines and because it has not been proven in head-to-head comparisons with surgery, the gold standard.
Is it necessary for endoscopic therapy to undergo comparative trials to prove itself once and for all as an accepted alternative to surgery? Endoscopic comparative studies for patients with complicated pancreatic disease are difficult to perform for a variety of reasons: the diseases are not so common as to allow ready enrollment without the need for randomized trials; the populations are heterogeneous and endpoints may be difficult to define; experienced pancreatic endoscopists are relatively uncommon and collaboration is needed from their surgical colleagues to participate and to enroll patients; funding is not readily available for these studies; and it may be unethical to enroll poor-operative patients into a study where they may be randomized to surgery. Finally, from my own experience, patients may be reluctant to enter a study when endoscopic therapy seems reasonable and avoids major surgery. Despite all these issues, pancreatic endotherapy will continue to make its way into mainstream treatment because of publications, such as the one by Musana et al. 3 in this issue of Clinical Medicine & Research, though it is important to note that pancreatic endotherapy is technically demanding, potentially dangerous, and should be restricted to high-volume centers with options for an interdisciplinary team approach. Well-designed, retrospective and prospective case series of endoscopic, radiological, and surgical techniques using accepted nomenclature 16 will allow us to make meaningful comparisons between disciplines and prove that endotherapy for complications of pancreatitis is effective and a solid surgical alternative.
It's 9 p.m. and your patient needs mechanical intervention of their pancreas. Do you know where your therapeutic endoscopist is?
